Biotechnology

Merck (MRK) is rumored to be pursuing Incyte (INCY), prompting market volatility.

Evotec has received a takeover offer from Halozyme, potentially creating a major player in life sciences. Retail investors should watch for market...

Natera's impressive Q3 2024 highlights its strong position in the genetic testing market.

Fungal outbreaks are increasing globally, impacting health systems and creating new investment opportunities in antifungal research and treatments.

Bristol Myers Squibb's Cobenfy, the first new schizophrenia treatment in over 70 years, offers hope for patients and investment potential for the...

See how Viridian Therapeutics (NASDAQ: VRDN) is innovating thyroid eye disease treatments with advanced therapies and a growing market opportunity.

Radiopharmaceuticals are revolutionizing cancer treatment, attracting billions in investments. Discover the potential and challenges for investors...

Roche's stock dropped 4.5% due to gastrointestinal side effects from its obesity drug CT-388, raising concerns among investors about the drug's...

Integra LifeSciences' commitment to quality compliance and supply chain resilience may yield growth opportunities for retail investors' portfolios.

Viking Therapeutics' fast-tracked weight loss injection could reshape the market, impacting investors' portfolios and strategies.

Dive into Biogen's impressive Q1 earnings, featuring an EPS beat and significant LEQEMBI sales growth. Explore what these results mean for the...

Contineum Therapeutics' IPO success reflects investor confidence in their innovative therapies for neuroscience, inflammation, and immunology.

J&J acquires Shockwave Medical for $13.1B, bolstering its medical device portfolio and positioning retail investors for potential growth in the...

Activist investor Carl Icahn spares Illumina a second proxy contest, but continues lawsuit, leaving retail investors curious about board dynamics...